NASDAQ | ETF
Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology.
The fund is non-diversified.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 6.07% |
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 5.44% |
| LEGN | Legend Biotech Corp | Healthcare | Biotechnology | 4.74% |
| NOVN | Novartis AG | Healthcare | Drug Manufacturers - General | 4.45% |
| RHHBY | Roche Holding Ltd ADR | Healthcare | Drug Manufacturers - General | 4.22% |
| UMRX | Cogent Biosciences Inc | Healthcare | Biotechnology | 4.20% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 3.71% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 3.56% |
| IMNM | Immunome Inc | Healthcare | Biotechnology | 3.36% |
| NUVL | Nuvalent Inc | Healthcare | Biotechnology | 3.35% |
| AZN | AstraZeneca PLC | Healthcare | Drug Manufacturers - General | 3.29% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 3.13% |
| ONC | BeiGene, Ltd. | Healthcare | Biotechnology | 3.09% |
| EXEL | Exelixis Inc | Healthcare | Biotechnology | 3.01% |
| IMGN | ImmunoGen Inc | Healthcare | Biotechnology | 3.00% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 2.96% |
| BBIO | BridgeBio Pharma Inc | Healthcare | Biotechnology | 2.87% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 2.77% |
| GMAB | Genmab AS | Healthcare | Biotechnology | 2.33% |
| CGON | CG Oncology, Inc. Common stock | Healthcare | Biotechnology | 2.30% |